Search PubMed⌕ Search

Biomedical subjects

M Pauchant

Publications and source records attributed to M Pauchant.

At least 19 recordsLinked to original sources
PubMed1989

[Evaluation of cicletanine efficiency and tolerance in hypertensive patients treated with beta-blockaders].

Efficacy and tolerance of cicletanine, the first derivative of furopyridines have been studied in a 3 parallel groups double blind study; 120 essential mild hypertensive patients uncontrolled by beta blocking therapy were included. After a period of one month during which a treatment by placebo was added to beta blocking therapy, the patients were randomly allocated into 3 groups: group I (placebo: 40 patients), group II (cicletanine 50 mg/d: 41 patients), group III (cicletanine 100 mg/d: 39 patients). Eight patients were withdrawn in the group I (poor efficacy, n = 5 or unexpected event, n = 3), and one in the group III (unexpected event). At the beginning of the treatment period (DO), lying blood pressure (LBP) was respectively for groups I, II and III 171 +/- 14/104 +/- 6, 174 +/- 13/104 +/- 5, 172 +/- 15/105 +/- 6 mmHg. 171 +/- 14/104 +/- 6, 174 +/- 13/104 +/- 5, 172 +/- 15/105 +/- 6 mmHg. After 3 months of treatment LBP was respectively 168 +/- 21/97 +/- 10, 151 +/- 12/85 +/- 7, 147 +/- 14/82 +/- 9 mmHg. A significant treatment effect (p less than 0.001) was observed on SBP with groups II and III only, and on DBP with the 3 groups. This lowering effect was comparable in groups II and III, and greater (p less than 0.001) in these groups than in group I. At the end of this study the percentage of patients whose BP was normalized was respectively for groups I, II and III: 5 p. 100, 51 p. 100 and 74 p. 100. Clinical and biological tolerance were good.(ABSTRACT TRUNCATED AT 250 WORDS)

Adrenergic beta-Antagonists↗
PubMed1989

[Evaluation of the effectiveness and tolerance of cicletanine in patients with essential hypertension treated with beta-blockers].

The effectiveness and safety of cicletanine hydrochloride, the first representative of the furopyridine family, were evaluated in a 90-day double-blind study involving 120 patients with moderate essential hypertension poorly controlled after at least one month of treatment with a beta-blocker. After a 30-day pre-inclusion period during which a placebo capsule was given together with a stable dose of the beta-blocker, the patients were randomised to one of three therapeutic groups: group 1 (placebo, n = 40), group 2 (cicletanine 50 mg/day, n = 41), group 3 (cicletanine 100 mg/day, n = 39). All three groups were matched in every respect. Eight patients in group I were excluded (5 for ineffectiveness, 2 for unexpected effect, 1 for intercurrent disease) as was 1 patient in group 3 for unexpected effect. On entering the active phase of treatment, supine blood pressures were 171.3 +/- 13.6/103.9 +/- 6.1 mmHg in group 1, 173.5 +/- 12.7/103.6 +/- 5.2 mmHg in group 2 and 171.8 +/- 15.4/104.5 +/- 5.9 mmHg in group 3. A significant (p less than 0.0001) treatment effect on SBP was found in groups 2 and 3 and on DBP in all three groups. The improvement observed in both SBP and DBP was similar in groups 2 and 3 and highly significant when compared with group 1 (p 0.001). At the end of the trial, 5% of group 1 patients, 51.2% of group 2 patients and 74.4% of group 3 patients had normal blood pressure values. The drug was well tolerated clinically and biochemically.(ABSTRACT TRUNCATED AT 250 WORDS)

Adrenergic beta-Antagonists↗
PubMed1982

[Dibekacin in the treatment of septicemia].

During an open multicentric trial (17 centers), we have treated 62 septicemia by dibekacin, alone or associated with other antibacterial drugs. Taking into account the degree of severity of these patients, the results are considered satisfactory in 47 patients. 15 failures were noted (including 9 deaths). General and local tolerance were good, in spite of the duration of treatment.

Adult↗